ISSN : ISSN: 2576-1412
Diabetes is a common comorbidity among heart failure patients. When two conditions coexist, the risk of cardiovascular morbidity and mortality skyrockets. As a result, it is critical to treat both disorders as soon as possible with the best available treatment. Advanced heart failure (AHF) therapies enhance the chances of survival in a growing number of people with stage D heart failure (HF). Referrals to AHF clinics must be made in a timely and suitable manner if these therapies are to be implemented successfully. Heart failure with a reduced ejection fraction is a severe condition with high morbidity, death, and societal costs.
Journal of Applied Microbiology and Biochemistry received 259 citations as per Google Scholar report